FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
NEW YORK, Dec. 04, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Zafgen, Inc. (Nasdaq:ZFGN) securities between January 12, 2015 and October 16, 2015.
Click here to learn about the case: http://docs.wongesq.com/ZFGN-Info-Request-Form-971. There is no cost or obligation to you.
The lawsuit alleges that Defendants made misrepresentations about thrombotic adverse events in previous clinical trials of its anti-obesity drug, and leading drug candidate, beloranib. Until October 16, 2015, Zafgen had disclosed only two thrombotic adverse events in one prior clinical trial.
On October 14, 2015, Zafgen issued a statement acknowledging the death of a patient in its ongoing Phase 3 study of beloranib. On October 15, 2015, the Food and Drug Administration informed Zafgen that beloranib had been placed on partial clinical hold. Then on October 16, 2015, Zafgen announced that: (i) the patient who died was receiving beloranib – not a placebo; and (ii) there had been four thrombotic adverse events in prior clinical studies of beloranib – two more than previously reported – as well as two additional, previously undisclosed thrombotic events in ongoing studies.
If you suffered a loss in Zafgen you have until December 21, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/ZFGN-Info-Request-Form-971.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
